5.54
-0.16(-2.81%)
Currency In USD
| Previous Close | 5.7 |
| Open | 5.62 |
| Day High | 5.83 |
| Day Low | 5.36 |
| 52-Week High | 23.5 |
| 52-Week Low | 2.9 |
| Volume | 60,063.78 |
| Average Volume | 311,504 |
| Market Cap | 13.96M |
| PE | 0.27 |
| EPS | 21.56 |
| Moving Average 50 Days | 5.75 |
| Moving Average 200 Days | 10.39 |
| Change | 0.07 |
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
GlobeNewswire Inc.
Feb 25, 2026 12:30 PM GMT
Unlocks market access and growth potential of REYOBIQ therapy in recurrent glioblastoma and pediatric brain cancer by enabling adoption and utilization trackingHOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
GlobeNewswire Inc.
Jan 22, 2026 12:45 PM GMT
Expands CNSide Clinical License in State of PennsylvaniaHOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceut
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
GlobeNewswire Inc.
Jan 21, 2026 9:15 PM GMT
HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today an